about
Towards tumor immunodiagnosticsMetabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsThe promise of immunotherapy in head and neck squamous cell carcinomaNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsPD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyPD-1 and its ligands are important immune checkpoints in cancerThe role of immune checkpoint inhibition in the treatment of ovarian cancerImaging Biomarkers in ImmunotherapyStructural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapyStructural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenIn vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.Indicators of responsiveness to immune checkpoint inhibitorsPrognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphomaMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorAnti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptorCancer immunotherapies targeting the PD-1 signaling pathway.Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Cellular immunity augmentation in mainstream oncologic therapyPDL-1/PD1 inhibitors: antibody or antinobody?Checkpoint inhibitors in bladder and renal cancers: results and perspectives.Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineCardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
P2860
Q26738691-91466CBD-96BD-4F2F-83BE-EC4E8A6C2571Q26740567-082B9FEB-5DED-41C4-B1E3-0E34AA0F83E3Q26744433-D6B0192C-D606-472D-A611-CE7E7A91CB04Q26769884-3BD7F89D-0870-4E95-B651-B6240C573B94Q26797478-FC2A5D2C-4264-4F5A-A656-A37001707D1AQ28067141-6B8132BB-DB6D-4FA1-A26D-FD069744D906Q28067939-4B691AEB-0771-4B68-93BE-4417C8AE893BQ28069485-0A37AB29-5BF5-4D21-B210-1B100EBFC64AQ28077924-A84DD245-474A-402B-89A8-40D6B67C1BCEQ28079871-4A8EA4FC-A61E-47F0-9727-DE9C33417EF4Q28314934-E74D88AA-AE3B-4532-80C8-BAC1F530FA25Q28822250-98507288-1CED-4F19-AA6B-67D3BFA712C8Q33576170-309D5A03-FE62-49C1-8068-D5CEF82D6657Q33605673-FC69154D-E0D6-4D6F-B0E2-DA3318ABB262Q33678048-A5A063AB-8087-4254-AE4E-9E7B8F9875BCQ33728267-8574828E-F297-497E-84C8-EA295632DE6BQ33738783-A5A742CC-0226-429C-BCC0-1F9F65740206Q34522172-4F6EEB73-A8CE-4652-9275-DF286700CDA5Q35934137-702FCACC-A80E-4209-AC34-49B66D471E2AQ35979344-5C770836-CFD4-43F9-BA07-A9DACE736128Q36173622-DE01B995-E425-4CB7-A959-7D658EFB6392Q36382143-9CC03082-0FE9-4309-89C3-566E1D4E590BQ36545353-3E8E62DD-9A71-4D44-BEBE-59D2E627E35BQ36962925-38F01556-E2A2-4A13-A67A-55963AE76256Q37014134-4CE8464D-C3E1-4B3C-9088-1C55DB6CD760Q37349280-DD1EFCF5-FCEC-4A83-B5B4-F4542B3956BDQ37474092-416BED83-E659-4B5D-A303-6F6096DD7185Q37621295-27F97368-7964-40D8-B207-69258574857DQ37644337-4BF10463-700E-43D3-87C6-01803A5E9B51Q37662169-87D71D51-2EFD-415A-9821-27480992864DQ37737940-D9262F3B-0737-4682-8FA6-0CFCBB3B357AQ38259896-DAE0B4F4-992B-4118-A0C0-801760DCCE96Q38557424-281C54EE-4985-44CE-B7D9-19ABEBB1F6FCQ38638443-7BEEF9E0-86DE-4E78-88E2-42B0B2FBCF7FQ38643514-EB02767E-6593-4EDE-8554-600CB39B0FD1Q38696133-ADFBAC7A-8EC7-4F47-B28F-81E0A31DB6A5Q38732716-61A6046B-CA76-41D9-8A85-C396F6731B71Q38735433-96C48826-5E32-4379-83BC-A48D4AE2665DQ38743088-1822BCF2-9D4E-4BD0-9F01-B97A2C158EA3Q38749966-67616900-2862-4EAC-89F4-A09C969CC445
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PD-1/PD-L1 inhibitors.
@ast
PD-1/PD-L1 inhibitors.
@en
type
label
PD-1/PD-L1 inhibitors.
@ast
PD-1/PD-L1 inhibitors.
@en
prefLabel
PD-1/PD-L1 inhibitors.
@ast
PD-1/PD-L1 inhibitors.
@en
P2860
P1476
PD-1/PD-L1 inhibitors
@en
P2093
Janis M Taube
P2860
P356
10.1016/J.COPH.2015.05.011
P577
2015-06-02T00:00:00Z